Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Preventing Impotence from Prostate Radiation

By HospiMedica staff writers
Posted on 03 Feb 2005
Radiation therapy for prostate cancer is successful for men with prostate cancer, however, up to 90% will develop impotence after the therapy. More...
A new study indicates that this side effect may be avoided if both magnetic resonance imaging (MRI) and computed tomography (CT) are utilized to strategize precisely how and where radiation will be deployed, rather than just CT.

Earlier studies have suggested that radiation on the prostate causes impotence by injuring the structures that control blood supply to the penis. Consequently, radiotherapy that avoids these structures could possibly preserve sexual function. According to researchers at the University of Michigan (UMich, Ann Arbor, MI, USA; www.umich.edu), with conventional CT therapy it is frequently believed that the distance between these major structures and the prostate is 1.5 cm; however, using this approximation on all patients is going to result in treating more tissue than is needed.

The UMich investigators used a combination of CT and MRI scanning to determine the precise distance from the prostate to the blood-containing structures in 25 men with prostate cancer. Even though the median distance--1.45 cm--was close enough to that used with CT-based therapy planning, the values differed extensively from 0-7-2.1 cm. The precise calculation of the distance permitted the group to be able to more precisely pinpoint radiotherapy to where it is needed to greatly reduce the dose to the vital erection structures.

Additional research is still needed to determine if combined CT and MRI planning of radiation therapy does in fact prevent impotence, according to the investigators, who published their results in the January 2005 issue of the International Journal of Radiation Oncology Biology Physics.




Related Links:
University of Michigan

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.